Reuters logo
BRIEF-Corvus Pharmaceuticals announces biomarker findings from phase 1/1b study of lead oral checkpoint inhibitor CPI-444
October 10, 2016 / 11:26 AM / a year ago

BRIEF-Corvus Pharmaceuticals announces biomarker findings from phase 1/1b study of lead oral checkpoint inhibitor CPI-444

Oct 10 (Reuters) - Corvus Pharmaceuticals Inc :

* Corvus Pharmaceuticals announces biomarker findings from phase 1/1b study of lead oral checkpoint inhibitor cpi-444 presented at ESMO 2016 congress

* Corvus Pharmaceuticals Inc - selected optimum single agent and combination dose of CPI-444 for disease-specific expansion stage of trial

* Corvus Pharmaceuticals Inc says CPI-444 has been well tolerated to date, with one patient experiencing a possibly drug related serious adverse event

* Corvus Pharmaceuticals - has selected an oral dose of 100 mg twice daily for 28 days for both single agent and combination arms of second part of trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below